COMPOSITION:
Each film-coated tablet contains
Vildagliptin ……………………………..50 mg
Metformin SR hydrochloride ……..500mg
DESCRIPTION:
Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults:
ACTION:
Vildana M combines two antihyperglycemic agents with different mechanisms of action to improve glycemic control in patients with type 2 diabetes: vildagliptin, a member of the DPP-4 (dipeptidyl-peptidase-4) inhibitor class and metformin hydrochloride, a member of the biguanide class. Vildagliptin, a member of the islet enhancer class, is a potent and selective dipeptidylpeptidase-4 (DPP-4) inhibitor that improves glycemic control. Vildagliptin inhibition of DPP4 results in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon- like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide). Metformin hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Metformin hydrochloride stimulates intracellular glycogen synthesis by acting on glycogen synthase and increase the transport capacity of specific types of membrane glucose transporters (GLUT-1 and GLUT-4).
INDICATIONS:
As an adjunct to diet and exercise, for patients whose diabetes is not adequately controlled on metformin hydrochloride or vildagliptin alone or as separate tablets, in combination with a sulfonylurea and as add-on to insulin.
CONTRAINDICATIONS:
Vildana M is contraindicated in patients with known hypersensitivity to vildagliptin or metformin hydrochloride or to any of the excipients